Phase I/II Trial: Weekly Carfilzomib, Pomalidomide, and Dexamethasone in R/R Multiple Myeloma

December 3-6, 2016; San Diego, California
Weekly carfilzomib with pomalidomide and low-dose dexamethasone appears effective with better tolerability in relapsed/refractory MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 454 KB
Released: December 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Downloadable slides from Clinical Care Options (CCO) with key takeaway points on newly approved agents for multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: February 2, 2021

Downloadable slides from Clinical Care Options (CCO) with nurse expert’s insights on available treatments, new approvals, and adverse event managements in patients with multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: January 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue